Jasper Therapeutics reports Q3 results
- Jasper Therapeutics press release (JSPR): Q3 Diluted loss per share of $10.19 vs. $32.08 Y/Y.
Revenue of $8K, compared with $0 Y/Y.
Net loss of $144.5M vs. $18.7M Y/Y, including $129.5M in acquired in-process R&D expense related to the Kira Pharmaceuticals acquisition.
Research and development expenses decreased 42% Y/Y to $8.3M.
General and administrative expenses increased 33% Y/Y to $6.4M.
Cash and cash equivalents totaled $135.3M as of September 30, 2026, compared with $28.7M as of December 31, 2025.
KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.